March 31, 2014Novozymes VELTIS® half-life extension technology used by GlaxoSmithKline in type 2 diabetes drug approved in Europe
March 13, 2014Novozymes Biopharma announces collaboration with Janssen to evaluate proprietary VELTIS half-life extension technology
January 21, 2014Novozymes Biopharma announces new data highlighting potential for monthly drug dosing
Sally VernonCustomer Communications ManagerTel.: +44 115 955 3355Fax: +44 115 955 1299Click here to email
Thomas Steenbech BomhoffSenior Manager of Investor RelationsTel.: +1 919 494 3483Fax: +1 919 494 3473Click here to email
Novozymes Biopharma is a part of Novozymes A/S and is listed on the NASDAQ, trading as NZYM B.
Copyright © 2014 Novozymes. All rights reserved.